Eli Lilly is approaching a $1.3 billion agreement with gene-editing biotech Verve Therapeutics, according to reports from the Financial Times

The Financial Times reported on Monday that Eli Lilly (LLY.N) is in advanced talks to buy gene editing startup Verve Therapeutics (VERV.O) for up to $1.3 billion. The company wants to improve its pipeline of experimental drugs by doing this.

People familiar with the matter told the report that the drug company’s offer to buy Verve includes an upfront payment of almost $1 billion and an additional $300 million if the genetic medicines company meets certain clinical goals.

The story also said that the deal could be made public as soon as this week, if talks go as planned.

Verve Therapeutics is working on a gene therapy to lower high cholesterol. This therapy will likely be used with other drugs.

Eli Lilly refused to say anything, and Verve Therapeutics did not answer right away when Reuters asked for a statement outside of normal business hours.